ADAPTVAC APS -  

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000

Ranking timeline:

Project Participation Performance(2020-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2022 0 9.999.995 1.820.875 1
2020 0 2.728.340 1.481.250 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM2
UNIVERSITY OF COPENHAGEN2
COUNCIL OF MALAWI UNIVERSITY OF SCIENCE AND TECHNOLOGY1
EUROPEAN VACCINE INITIATIVE EWIV1
EXPRES2ION BIOTECHNOLOGIES APS1
FONDATION POUR LA RECHERCHE SCIENTIFIQUE1
GHANA HEALTH SERVICE1
GROUPE DE RECHERCHE ACTION EN SANTE SARL1
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT1
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE1
LEIDS UNIVERSITAIR MEDISCH CENTRUM1
STICHTING RADBOUD UNIVERSITEIT1
THE UNIVERSITY OF TUEBINGEN1
UNIVERSITAETSKLINIKUM TUEBINGEN1
WAGENINGEN UNIVERSITY1

Constancy:

Total number of partners: 17
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 17
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2022-06-01Advancing The Clinical Development Of Placental Malaria Vaccines In The Context Of Capacity Building and Use Of Digital Health Technologies ADVANCE-VAC4PMparticipant9.999.99510
2020-04-01Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine Prevent-nCoVparticipant2.728.3409